Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has earned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $22.57.

Several analysts have weighed in on NMRA shares. William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a research report on Friday, April 12th. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price objective on shares of Neumora Therapeutics in a report on Thursday, March 28th. Finally, JPMorgan Chase & Co. raised their target price on Neumora Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th.

Neumora Therapeutics Trading Up 0.1 %

NASDAQ NMRA opened at $9.10 on Friday. Neumora Therapeutics has a one year low of $8.82 and a one year high of $21.00. The business’s fifty day moving average is $14.07 and its 200-day moving average is $14.07.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.05. Equities analysts predict that Neumora Therapeutics will post -1.48 EPS for the current year.

Institutional Trading of Neumora Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Amalgamated Bank purchased a new position in Neumora Therapeutics in the fourth quarter valued at $29,000. Tower Research Capital LLC TRC purchased a new position in Neumora Therapeutics in the 4th quarter valued at $44,000. Strs Ohio acquired a new position in shares of Neumora Therapeutics during the fourth quarter worth about $54,000. SG Americas Securities LLC acquired a new position in Neumora Therapeutics during the 4th quarter worth approximately $108,000. Finally, New York State Common Retirement Fund acquired a new position in Neumora Therapeutics during the fourth quarter worth $118,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.